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Abstract
The prevalence of clonal complex (CC) 398 methicillin-susceptible
Staphylococcus aureus (MSSA) was unexpectedly high among bone
and joint infections (BJIs) and nasal-colonizing isolates in France,
with surprising geographical heterogeneity. With none of the
major, most-known staphylococcal virulence genes, MSSA CC398
BJI was associated with lower biological inﬂammatory syndrome
and lower treatment failure rates.
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In addition to being a frequent colonizing organism, Staphylo-
coccus aureus is one of the leading causes of human suppurative
infections, such as bone and joint infections (BJIs). Although
wild isolates are susceptible to methicillin (methicillin-suscep-
tible S. aureus (MSSA)), methicillin-resistant S. aureus (MRSA)
isolates emerged from MSSA initially in hospital settings
(so-called hospital-acquired MRSA) and then in the community
(community-acquired MRSA) by acquiring the SCCmec ele-
ment harbouring the mecA gene, which encodes a speciﬁc
penicillin-binding protein (PBP2a). In the past 10 years,
livestock has been described as a third MRSA reservoir
(livestock-associated MRSA), notably because of the world-
wide spread of MRSA of sequence type (ST) 398 or related
STs clustered in clonal complex (CC) 398 [1,2]. Initially
reported as an animal colonizer, MRSA CC398 has been
shown to be responsible for various human infections [2].
Whole genome sequence analysis has provided evidence that
this MRSA clone probably originated in humans as MSSA, and
then jumped to livestock, where it acquired methicillin resis-
tance-associated genes [1]. However, little is known about this
MSSA CC398 counterpart. Poorly described in animals, this
clone was recently reported in people lacking livestock-asso-
ciated risk factors as a rare pathogen in various conditions such
as bloodstream, respiratory tract and skin and soft tissue
infections, and infective endocarditis in several countries, as
well as a rare human nasal commensal [3–7]. However, the role
of MSSA CC398 in BJIs has not been described.
To investigate MSSA CC398 in BJIs, we conducted a
retrospective study of all patients with monomicrobial or
polymicrobial MSSA BJI (i.e. clinical evidence of infection and at
least one reliable MSSA-positive bacteriological sample) diag-
nosed in four French geographical areas between 2009 and
2012 (Fig. 1). Because nasal carriage of staphylococci is
associated with a high risk of S. aureus infection, a control
population of nasal-colonizing isolates was established in two
of the participating centres, obtained by nasal sampling of
patients admitted for orthopaedic surgery (excluding patients
with BJIs) or in intensive-care units. S. aureus characterization
was initially performed with the automated system Vitek-2
(bioMerieux, Marcy l’Etoile, France).
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A total of 485 isolates from patients with MSSA BJIs (Lyon,
n = 173 (Hospices Civils de Lyon, n = 75; Novescia, n = 98);
Montpellier, n = 132; Saint-Etienne, n = 96; Paris, n = 84)
were screened by the use of CC398-speciﬁc PCR targeting the
sau1–hsdS1 gene, as previously described [8]. Within this
MSSA BJI collection, 68 of the 485 isolates (14.0%) belonged to
CC398. For comparison, 31 (9.0%) of the 346 nasal-colonizing
MSSA isolates (Hospices Civils de Lyon, from 2010 to 2012,
n = 228; Montpellier, 2012, n = 118) were CC398. Because
most previous international staphylococcal clonal distribution
studies have mainly focused on MRSA, it is difﬁcult to
determine whether this clone is emerging or has been
neglected thus far. However, several facts argue for emer-
gence. Concerning nasal-colonizing strains, CC398 accounted
for only two of 829 (0.2%) MSSA isolates in a Dutch study
published in 2008, and two of 52 (3.8%) Spanish MSSA isolates
in 2009 [3,4]. With respect to BJIs, Luedicke et al. reported a
high diversity of staphylococcal genetic backgrounds for the
2005–2006 period in Germany, with a distribution of the major
CCs similar to that in our study, but no CC398 [9]. These
differences may have been inﬂuenced by geographical area, but
the hypothesis that this clone emerged and rapidly spread is
supported by the fact that only one CC398 strain was
identiﬁed in 2008 during screening of BJI MSSA strains isolated
in our hospital in the period between 2001 and 2008 among 52
isolates (1.9%; p 0.081).
Surprisingly, heterogeneity in geographical distribution was
observed. The prevalence of CC398 among MSSA BJI
isolates was only 3.1% in Saint-Etienne, reached 10.4% in
Lyon, and was as high as 19.0% in Paris and 23.5% in
Montpellier. The frequency in Montpellier was signiﬁcantly
different from that observed in Saint-Etienne (p 0.002) and
Lyon (p 0.009), and the frequency in Paris was different from
that in Saint-Etienne (p 0.002) and Lyon (p 0.046). It is of
note that the lower prevalence of MSSA CC398 was found
in two cities that are close to each other (Lyon and
Saint-Etienne; 50 km). Similarly, an important difference was
observed in MSSA CC398 rate among nasal-colonizing
isolates between Lyon (n = 9/228; 3.9%) and Montpellier
(n = 22/118; 18.6%; p 0.013). This heterogeneity in geo-
graphical prevalence raises the question of the driving
mechanism. It may lie in greater endemic diffusion in some
areas, possibly related to speciﬁc routes of transmission, risk
factors, and environmental conditions, or the emergence of
subpopulations associated with the acquisition of particular
genetic traits in other areas.
FIG. 1. Map showing the four geographical areas included in the study.
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In an ancillary study, MSSA BJIs identiﬁed in our hospital
(n = 75) between 2011 and 2012 were extensively character-
ized with respect to genetic background, virulence and
resistance genes, and clinical characteristics. CC assignment
on the basis of DNA microarray results (StaphyType; Alere,
Jena, Germany) was in agreement with the CC398-speciﬁc
PCR results [10,11]. As expected for the MSSA collection, a
great diversity of CCs was observed (n = 20), among which
CC398 was the fourth most common (n = 8; 10.7%), behind
CC30 (n = 12; 16.0%), CC5 (n = 10; 13.3%), and CC45
(n = 9; 12.0%). CC398 was associated with three different spa
types, namely t571 (n = 6), t034 (n = 1), and t002 (n = 1). No
signiﬁcant differences were observed between CC398 and
other strains with respect to demographic characteristics and
the clinical presentation of BJIs (Table 1). Conversely, MSSA
CC398 BJIs were signiﬁcantly associated with a lower
biological inﬂammatory syndrome (p 0.035) and lower treat-
ment failure rates (0% vs. 37.3%, p 0.032). These results should
be interpreted with caution, because of the large number of
statistical tests performed and the small number of included
cases of each clone. Nevertheless, this low virulence proﬁle is
in agreement with DNA microarray analysis revealing no
particular resistance gene (except for an isolated resistance
to macrolides related to the ermT gene), and none of the
major, most well-known staphylococcal virulence genes, with
the exception of one strain bearing the genes for enterotox-
ins C and L. This may also explain why this ‘unspecialized’
pathogen is associated with a large panel of diseases [3–7].
However, all strains harboured the chp and scn genes on a
mobile genetic element belonging to the immune evasion
cluster and b-haemolysin-converting bacteriophages and
described as being associated with S. aureus human host
speciﬁcity for the ST398 lineage that has been lost in the
animal-adapted MRSA CC398 [1,12]. The presence of such
mobile genetic elements provides evidence for the capacity of
the MSSA CC398 clone to be highly receptive to horizontal
gene transfer, which might lead to human and/or virulence
adaptation. This hypothesis was recently conﬁrmed by the
emergence and spread of a Panton–Valentine leukoci-
din-positive CC398 subpopulation in Chinese skin and soft
tissue infections, reaching 64.3% of CC398 isolates in a recent
study [13]. This last report is very worrying; the acquisition of
this hypervirulent phenotype by a clone that is well adapted to
humans and able to be transmitted throughout the community
(as demonstrated by high nasal colonization rates in some
areas) may have a major impact on public health, and warrants
regular monitoring.
Finally, a particular ability of this clone to cause BJIs remains
questionable. On the one hand, the high prevalence of MSSA
CC398 in BJIs and the difference between BJI and nasal-col-
onizing isolates, especially in our institution (nine MSSA
CC398/228 nasal-colonizing isolates (3.9%) as compared with
10.4% CC398 BJIs (p 0.028)), suggest a particular tropism of
this clone for bone and joints. In Montpellier, the very
widespread diffusion of the clone as indicated by the huge
prevalence, even in carriage (23.5% of all MSSA), possibly
masks the phenomenon, and makes it more difﬁcult to obtain
statistically signiﬁcant data when comparing the prevalence of
CC398 in BJIs and carriage. On the other hand, a global rise in
the prevalence of MSSA CC398 has been observed in France in
various pathogenic conditions, including bloodstream infec-
tions [5,7]. Moreover, DNA microarray analysis failed to
highlight speciﬁc genetic virulence associated with BJIs. In any
case, this rise in MSSA CC398 prevalence in BJIs as well as in
many other infectious conditions may be attributable to
speciﬁc unknown virulence factors or speciﬁc expression
TABLE 1. Characteristics of the 75 patients with methicil-
lin-susceptible Staphylococcus aureus (MSSA) bone and joint
infection (BJI) included at the Lyon University Hospitals, and
comparison between clonal complex (CC) 398 and other
clones
Total CC398 Other clones p
Total patients 75 8 67
Demographic characteristics
Sex (male) 47 (62.7) 6 (75.0) 41 (61.2) 0.364
Age (years) 52.7  20.3 49.9  17.0 53.1  20.7 0.377
Charlson’s
comorbidity index
2.4  2.8 1.8  2.7 2.5  2.8 0.492
BJI characteristics
Arthritis 26 (34.7) 4 (50) 22 (32.8) 0.278
Prosthesis
joint infections
16 (21.3) 1 (12.5) 15 (22.4) 0.455
Osteomyelitis 38 (50.7) 4 (50) 34 (50.7) 0.629
Osteosynthesis
device infections
25 (33.3) 4 (50) 21 (31.3) 0.249
Vertebral
osteomyelitis
11 (14.7) 0 (0) 11 (16.4) 0.262
Vertebral
osteosynthesis
device infections
5 (6.7) 0 (0) 5 (7.5) 0.560
Acute BJI 47 (62.7) 6 (75) 41 (61.2) 0.364
Delay from
symptoms to
diagnosis (days)
52.5  362.9 3.4  3.3 58.4  383.9 0.246
Biological
inﬂammatory
syndrome
67 (89.3) 5 (62.5) 62 (92.5) 0.035
CRP (mg/L) 110  113 62  96 116  115 0.193
Leukocyte
count (109/mL)
10.2  4.2 7.6  2.3 10.5  4.2 0.048
Neutrophil
count (109/mL)
7.8  4.0 5.3  2.0 8.1  4.1 0.035
Local complication 58 (77.3) 6 (75) 52 (77.6) 0.583
Fistula 38 (50.7) 2 (25) 36 (53.7) 0.122
Abscess 31 (41.3) 5 (62.5) 26 (38.8) 0.182
Bacteraemia 22/33 (66.7) 1/2 (50) 21/31 (67.7) 0.562
Outcome
Treatment failure 25 (33.3) 0 (0) 25 (37.3) 0.032
CRP, C-reactive protein. Acute BJI: time from the onset of symptoms to diagnosis
of ≤4 weeks. Biological inﬂammatory syndrome: CRP level of >10 mg/L at the time
of diagnosis. Treatment failure: (i) persistence of septic symptoms despite
appropriate surgical and medical treatment; (ii) relapse owing to the same MSSA
after cessation of treatment; or (iii) the need for a new operation for sepsis more
than 5 days after the initial operation.
Results are presented as n (%) and mean  standard deviation. Comparisons were
performed by use of a t-test with Welch’s correction for continuous variables, and
the chi-squared or Fisher exact test for dichotomous variables, as appropriate.
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proﬁles impacting on phenotypic characteristics, such as
bioﬁlm formation and/or interactions with bone cells, which
remain to be evaluated.
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